Clinical Trials Browser

Has results × Neoplasms × veliparib × Clear all

NCT02723864 2022-02-08

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Phase 1 Completed

53 enrolled 20 charts

Neoplasms